Breast Cancer

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.

Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

Axillary RFS at 3 years was noninferior with less vs more invasive staging procedures in node-negative breast cancer after neoadjuvant chemotherapy.

Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Locoregional recurrence-free rates were similar in newly diagnosed breast cancer, irrespective of resection of MRI-detected disease.

Patients with early breast cancer who received pembrolizumab plus radiation therapy experienced significant improvements in T-Cell infiltration and promising pCR rates.

Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.

Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.

PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.

Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.

Dionisia Quiroga, DO, PhD, discusses breast cancer insights.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.